

Catherine Tomaro-Duchesneau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/388256/publications.pdf>

Version: 2024-02-01

31
papers

4,761
citations

304602

22
h-index

454834

30
g-index

32
all docs

32
docs citations

32
times ranked

11224
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease. <i>Scientific Reports</i> , 2020, 10, 4922.	1.6	22
2	Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by <i>Enterococcus faecalis</i> Metalloprotease GelE. <i>MSphere</i> , 2020, 5, .	1.3	14
3	Human Intestinal Enteroids With Inducible Neurogenin-3 Expression as a Novel Model of Gut Hormone Secretion. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 209-229.	2.3	60
4	<i>Lactobacillus fermentum</i> NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. <i>Beneficial Microbes</i> , 2015, 6, 861-869.	1.0	17
5	Cholesterol Assimilation by <i>Lactobacillus</i> Probiotic Bacteria: An In Vitro Investigation. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	103
6	The gut microbiome, probiotics, bile acids axis, and human health. <i>Trends in Microbiology</i> , 2014, 22, 306-308.	3.5	53
7	866: Screening of <i>Lactobacillus reuteri</i> strains for their short chain fatty acids production, stability and potential in colorectal cancer: In-vitro analysis. <i>European Journal of Cancer</i> , 2014, 50, S212.	1.3	1
8	Effect of orally administered <i>L. fermentum</i> NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. <i>Applied Microbiology and Biotechnology</i> , 2014, 98, 115-126.	1.7	57
9	Enrichment of <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 within the human gut microbiota using alginate-poly-L-lysine-alginate microencapsulation oral delivery system: an in vitro analysis using a computer-controlled dynamic human gastrointestinal model. <i>Journal of Microencapsulation</i> , 2014, 31, 230-238.	1.2	6
10	Microencapsulated <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 Favorably Modulates Gut Microbiota and Reduces Circulating Endotoxins in F344 Rats. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	2,927
11	Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. <i>Beneficial Microbes</i> , 2014, 5, 447-460.	1.0	27
12	Intranasal Delivery of Chitosan-siRNA Nanoparticle Formulation to the Brain. <i>Methods in Molecular Biology</i> , 2014, 1141, 233-247.	0.4	12
13	Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action. <i>Current Pharmaceutical Design</i> , 2014, 20, 1025-1037.	0.9	26
14	Design of a novel gut bacterial adhesion model for probiotic applications. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2013, 41, 116-124.	1.9	9
15	Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. <i>Biomaterials</i> , 2013, 34, 1270-1280.	5.7	161
16	Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. <i>Journal of Medical Microbiology</i> , 2013, 62, 1107-1123.	0.7	118
17	Effect of Probiotics <i>Lactobacillus</i> and <i>Bifidobacterium</i> on Gut-Derived Lipopolysaccharides and Inflammatory Cytokines: An In Vitro Study Using a Human Colonic Microbiota Model. <i>Journal of Microbiology and Biotechnology</i> , 2013, 23, 518-526.	0.9	129
18	Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 631-642.	1.4	140

#	ARTICLE	IF	CITATIONS
19	Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: <i>in vitro</i> preparation and characterization. <i>Expert Opinion on Drug Delivery</i> , 2013, 10, 1471-1482.	2.4	36
20	Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. <i>International Journal of Biomaterials</i> , 2013, 2013, 1-13.	1.1	23
21	Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. <i>International Journal of Nanomedicine</i> , 2013, 8, 2041.	3.3	60
22	Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles. <i>Journal of Pharmaceutics</i> , 2013, 2013, 1-10.	4.6	20
23	Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions. <i>Journal of Pharmaceutics</i> , 2013, 2013, 1-19.	4.6	40
24	Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters. <i>PLoS ONE</i> , 2013, 8, e58394.	1.1	38
25	Probiotic Ferulic Acid Esterase Active <i>Lactobacillus fermentum</i> NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and <i>in vitro</i> Characterization. <i>Pharmaceutics</i> , 2012, 5, 236-248.	1.7	53
26	Probiotics as oral health biotherapeutics. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1207-1220.	1.4	48
27	A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and <i>in vitro</i> analysis. <i>International Journal of Nanomedicine</i> , 2011, 6, 485.	3.3	61
28	Gut microbiota: next frontier in understanding human health and development of biotherapeutics. <i>Biologics: Targets and Therapy</i> , 2011, 5, 71.	3.0	181
29	Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1340-1351.	6.6	226
30	The Gut Microbiota and Human Health with an Emphasis on the Use of Microencapsulated Bacterial Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-12.	3.0	71
31	Transit Time Affects the Community Stability of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Species in an <i>In Vitro</i> Model of Human Colonic Microbiota. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2011, 39, 351-356.	0.9	22